Statin Therapy in the Treatment of Sepsis

NCT00676897 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2017-06-14

Study results available
· View outcomes & findings →

Summary

Simvastatin will attenutat IL-6 levels and lead to a more rapid shock reversal than placebo

Conditions

  • Septic Shock

Interventions

DRUG

Simvastatin

Simvastatin 40mg PO or NGT

DRUG

Placebo

Corn Starch

Sponsors & Collaborators

Principal Investigators

  • Michael W Donnino, MD · Beth Israel Deaconess Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00676897 on ClinicalTrials.gov